Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

KalVista Pharmaceuticals Presents Data Showing Rapid Reduction of Plasma Kallikrein Activity After Oral KVD900 Treatment and Early Symptom Relief From HAE Attacks in Patients

KVD900 Phase 2 data presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Scientific Meeting

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented data for its lead oral drug candidate, KVD900, in development for on-demand treatment of hereditary angioedema (HAE), at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Scientific Meeting.

KalVista Pharmaceuticals notes data presentations included new data from the Phase 2 trial highlighting rapid suppression of plasma kallikrein activity after KVD900 administration and its relationship with symptomatic relief.

“These data from our phase 2 trial in on-demand use for HAE attacks show that oral KVD900 is quickly absorbed, leading to rapid, near-complete suppression of plasma kallikrein activity, a key mediator of HAE attacks,” said Andrew Crockett, Chief Executive Officer of KalVista. “We believe that this rapid absorption followed by rapid suppression of plasma kallikrein activity is the basis for the early symptom relief we observed in the trial.”

The following posters were presented at AAAAI:

Poster Title: Rapid Plasma Kallikrein Inhibition Following Oral KVD900 is Associated with Early Symptom Relief in Patients with Hereditary Angioedema

  • KVD900 was rapidly absorbed, reaching maximum plasma concentrations within 1 hour
  • Plasma kallikrein activity was >80% inhibited within 15 minutes with near-complete inhibition (>95%) observed within 1 hour
  • A significantly shorter median time (1.6 hrs.) to symptom relief was observed in patients receiving KDV900 compared with placebo (9 hrs.)

Poster Title: Agreement of Patient Global Impression of Change (PGI-C) with Attack Resolution or Use of Rescue Mediation in Patients with Hereditary Angioedema

  • 113 HAE attacks were treated in a blinded manner with either KVD900 or placebo
  • Symptom relief, as captured by improvement on the PGI-C, occurred in 72% of attacks within 24 hours, and among those only 16% of HAE attacks were associated with use of rescue medication, while approximately 60% achieved complete attack resolution without use of rescue
  • Conversely, for the 28% of attacks where symptom relief was not achieved, 66% were associated with use of rescue medication and less than 4% achieved complete attack resolution without use of rescue
  • PGI-C is an effective tool to monitor attack symptoms may be an early predictor of attack resolution in patients with HAE

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine